Eli Lilly and Co Analyst Ratings
Jefferies Maintains Buy on Eli Lilly and Co, Raises Price Target to $957
Axsome Therapeutics Analyst Ratings
HSBC Adjusts Price Target on Merck & Co. to $130 From $118, Keeps Hold Rating
Merck & Co Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $155 Price Target
Corcept Therapeutics Analyst Ratings
Truist Adjusts Price Target on Corcept Therapeutics to $65 From $44, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Ultragenyx Pharmaceutical (RARE)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Veeva Systems (VEEV), Intra-Cellular Therapies (ITCI) and Phreesia (PHR)
Eli Lilly: Goldman Sachs raised the target price from $740 to $785
Wells Fargo Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
Balanced Outlook Amidst Strategic Shifts: Pfizer's Hold Rating Explained
Pfizer's Acoramidis Shows Promising Survival Trends: A Buy Rating Endorsement
Goldman Sachs Adjusts Price Target on Eli Lilly to $785 From $740
Truist Financial Sticks to Its Buy Rating for Corcept Therapeutics (CORT)
Corcept Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Theravance Biopharma (TBPH) and Merus (MRUS)
Barclays Sticks to Their Buy Rating for Elanco Animal Health (ELAN)
Analysts' Top Healthcare Picks: Axsome Therapeutics (AXSM), Werewolf Therapeutics (HOWL)